{"id":"NCT00500357","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","briefTitle":"Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Elderly Subjects","officialTitle":"A Phase 3, Open-Label, Single-Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of a Subsequent Dose of 13-valent Pneumococcal Conjugate Vaccine Administered to One Group of Individuals Who Participated in Study 6115A1-500","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-11","primaryCompletion":"2010-01","completion":"2010-01","firstPosted":"2007-07-12","resultsPosted":"2011-02-17","lastUpdate":"2011-04-19"},"enrollment":105,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Vaccines, Pneumococcal Conjugate Vaccine"],"interventions":[{"type":"BIOLOGICAL","name":"13-valent Pneumococcal Conjugate Vaccine","otherNames":[]}],"arms":[],"summary":"This is a follow-up study to the core study NCT00269672 (6115A1-500). This study will further evaluate the safety, tolerability, and immunogenicity of 13-valent pneumococcal conjugate vaccine (13vPnC) when administered to subjects who have already received one dose of 13vPnC, and one dose of 23-valent pneumococcal polysaccharide vaccine (23vPS) one year later. This study will determine if a subsequent dose of 13vPnC one year later results in similar or greater immune response (body's ability to protect against disease) than that measured after the initial dose of 13vPnC.","primaryOutcome":{"measure":"Pneumococcal OPA Geometric Mean Titers (GMTs) for the 13 Serotypes 1 Month After 13vPnC / 23vPS / 13vPnC (Vaccination 3) Versus 1 Month After 13vPnC (Vaccination 1)","timeFrame":"Month 1 / Year 0 (Core study/NCT00269672), Month 1 / Year 2 (Follow-up study/NCT00500357)","effectByArm":[{"arm":"13vPnC (Vax 1 Core Study/NCT00269672)","deltaMin":198,"sd":null},{"arm":"13vPnC / 23vPS / 13vPnC (Vax 3 Follow-up Study/NCT00500357)","deltaMin":78,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"65 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":16,"countries":["South Africa"]},"refs":{"pmids":["24576885"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":105},"commonTop":["Fatigue","Headache","Injection site pain","Injection site erythema","Myalgia"]}}